This Article Full Text Full Text (PDF) Supplementary Data Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Mortarini, R. Articles by Anichini, A. Search for Related Content PubMed PubMed Citation Articles by Mortarini, R. Articles by Anichini, A.

Constitutive Expression and Costimulatory Function of LIGHT/TNFSF14 on Human Melanoma Cells and Melanoma-Derived Microvesicles

¹ Human Tumor Immunobiology Unit, Department of Experimental Oncology, ² Department of Pathology, and ³ Melanoma and Sarcoma Unit, Department of Surgery, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy

Requests for reprints: Andrea Anichini, Human Tumor Immunobiology Unit, Department of Experimental Oncology, Istituto Nazionale per lo Studio e la Cura dei Tumori, Via Venezian 1, 20133 Milan, Italy. Phone: 39-22-390-2817; Fax: 39-22-390-2630; E-mail: andrea.anichini{at}istitutotumori.mi.it.

Neoplastic cells are thought to have defective expression of costimulatory molecules. However, in this study, we show that human melanoma cells express LIGHT/TNFSF14, a ligand of herpesvirus entry mediator on T cells and of lymphotoxin ß receptor on stromal cells. In vitro, melanoma cells stained for LIGHT in the intracellular compartment, with weak or negative cell surface expression. However, LIGHT was expressed on tumor-derived microvesicles released from melanoma cells. In vivo, LIGHT was found in metastatic lesions, and the extent of lymphotoxin ß receptor expression on the stromal cells was significantly associated with a "brisk" T-cell infiltrate in the neoplastic tissue. In the lesions with a brisk T-cell infiltrate, stromal cells surrounding the tumor also stained for the T-cell attractant chemokine CCL21. The intratumoral T lymphocytes frequently expressed herpesvirus entry mediator and were characterized by a differentiated phenotype. Coculture of lymphocytes with LIGHT⁺ melanoma-derived microvesicles or even with LIGHT⁺ melanoma cells in the presence of interleukin-2 costimulated LIGHT-dependent CD3⁺CD8⁺ T-cell proliferation. However, lymphocyte coculture with LIGHT⁺ microvesicles in the presence of interleukin-2 was also associated with an apoptotic response as documented by increased binding of Annexin V by CD3⁺CD8⁺ T cells. These data suggest that LIGHT constitutively expressed in human melanoma cells and microvesicles may contribute to regulate T-cell responses to tumor cells.

This article has been cited by other articles:

				J. Pan, Q. Zhang, J. Zhou, D. Ma, X. Xiao, and D. W. Wang Recombinant adeno-associated virus encoding Epstein-Barr virus latent membrane proteins fused with heat shock protein as a potential vaccine for nasopharyngeal carcinoma Mol. Cancer Ther., September 1, 2009; 8(9): 2754 - 2761. [Abstract] [Full Text] [PDF]

				R. Mortarini, C. Vegetti, A. Molla, F. Arienti, F. Ravagnani, A. Maurichi, R. Patuzzo, M. Santinami, and A. Anichini Impaired STAT Phosphorylation in T Cells from Melanoma Patients in Response to IL-2: Association with Clinical Stage Clin. Cancer Res., June 15, 2009; 15(12): 4085 - 4094. [Abstract] [Full Text] [PDF]

				P. Dhawan, Y. Su, Y. M. Thu, Y. Yu, P. Baugher, D. L. Ellis, T. Sobolik-Delmaire, M. Kelley, T. C. Cheung, C. F. Ware, et al. The Lymphotoxin-{beta} Receptor Is an Upstream Activator of NF-{kappa}B-mediated Transcription in Melanoma Cells J. Biol. Chem., May 30, 2008; 283(22): 15399 - 15408. [Abstract] [Full Text] [PDF]

				J. P. Edwards, X. Zhang, K. A. Frauwirth, and D. M. Mosser Biochemical and functional characterization of three activated macrophage populations J. Leukoc. Biol., December 1, 2006; 80(6): 1298 - 1307. [Abstract] [Full Text] [PDF]

				M. Lukashev, D. LePage, C. Wilson, V. Bailly, E. Garber, A. Lukashin, A. Ngam-ek, W. Zeng, N. Allaire, S. Perrin, et al. Targeting the Lymphotoxin-{beta} Receptor with Agonist Antibodies as a Potential Cancer Therapy Cancer Res., October 1, 2006; 66(19): 9617 - 9624. [Abstract] [Full Text] [PDF]

				Z. Fan, P. Yu, Y. Wang, Y. Wang, M. L. Fu, W. Liu, Y. Sun, and Y.-X. Fu NK-cell activation by LIGHT triggers tumor-specific CD8+ T-cell immunity to reject established tumors Blood, February 15, 2006; 107(4): 1342 - 1351. [Abstract] [Full Text] [PDF]